Sat.Feb 24, 2024 - Fri.Mar 01, 2024

article thumbnail

STAT+: Change Healthcare cyber attack outage could persist for weeks, UnitedHealth Group executive suggests

STAT

The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive suggested in a Tuesday conference call with hospital cybersecurity officers, according to a recording obtained by STAT. UnitedHealth Group Chief Operating Officer Dirk McMahon said the company is setting up a loan program to help providers who can’t submit insurance claims while Change is offline.

Hospitals 363
article thumbnail

SAEM Clinical Images Series: Neonatal Rash

ALiEM - Pharm Pearls

An 18-day-old male presented for a rash on his face for two days. The patient was born via spontaneous vaginal delivery full term without complications to a mom who has a history of genital HSV but without active lesions at delivery and on acyclovir. The patient presented with a vesicular rash on his face including around his eyes. He had conjunctival discharge noted by mom.

195
195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biogen partner NeuroSense seeks a role in the ALS revolution

PharmaVoice

Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

195
195
article thumbnail

Nearly 400,000 vape kits to be sent to smokers

The Pharmacist

Nearly 400,000 vape kits are set to be sent to smokers in England under the government’s swap-to-stop scheme, our sister title Healthcare Leader has exclusively revealed. At least four integrated care boards (ICBs) and more than 80 localities have expressed interest in the scheme with 379,562 ‘vape starter kits’ requested as of February 2024, data […] The post Nearly 400,000 vape kits to be sent to smokers appeared first on The Pharmacist.

127
127
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

CDC advisory panel says people 65 and older should get a Covid spring booster shot

STAT

An expert panel advising the Centers for Disease Control and Prevention on vaccines on Wednesday recommended that people 65 and older should get an additional Covid-19 vaccine shot this spring. The recommendation was approved by CDC Director Mandy Cohen, allowing the United States to join Canada and the United Kingdom in offering a spring booster this year to people at high risk of severe disease if they contract Covid.

Vaccines 363
article thumbnail

SAEM Clinical Images Series: Two Pupils for the Price of One

ALiEM - Pharm Pearls

A 24-year-old female with no pertinent PMHx presents to the ED with a chief complaint of eye pain. She reported a 10-day history of worsening right eye pain following being punched in that eye. She had been managing her pain with ice and had not taken any OTC medications. Her mom convinced her to go to the ED and she first went to an outside hospital, but was referred to come to our institution.

Hospitals 152

More Trending

article thumbnail

Scaling innovation across hospitals and nations

pharmaphorum

Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.

Hospitals 122
article thumbnail

‘Brain fog’ is one of Covid-19’s most daunting symptoms. A new study measures its impact

STAT

Of all the lingering symptoms of long Covid , difficulty focusing and thinking, known as brain fog , may be the most frightening and baffling. A new study published Wednesday in the New England Journal of Medicine, which looks at how much cognition is impaired in the months after a coronavirus infection, shows that Covid-19’s impact can be measured in the equivalent of IQ points.

Hospitals 363
article thumbnail

Viking data suggest obesity drug could rival Zepbound, Wegovy

BioPharma Dive

The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

122
122
article thumbnail

FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two years: GlobalData

Express Pharma

Following the news that the FDA denied approval for Minerva Neurosciences for its roluperidone for the treatment of negative symptoms in patients with schizophrenia; Christie Wong, Neurology Analyst at GlobalData, offers her view: “The FDA has issued a Complete Response Letter (CRL) for Minerva Neurosciences’ roluperidone. It follows a refusal to file in October 2022 and two FDA Type C meetings in November 2020 and March 2022.

114
114
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Why is pharma going gaga for radiopharmaceuticals?

pharmaphorum

Pharmaceutical companies are increasingly focusing on radiopharmaceuticals due to their potential in oncology and therapeutic applications. Learn more about why the industry is excited about radioisotopes in this article.

article thumbnail

Opinion: Medicare Advantage is bad for patients and bad for investors

STAT

In 2023, enrollment in Medicare Advantage, the version of Medicare run by private insurers, surpassed 50% of eligible beneficiaries for the very first time. Going by this headline, or perhaps the predictable flood of advertisements for plans during the fall’s open enrollment period, you might be fooled into thinking 2023 was MA’s best year yet.

363
363
article thumbnail

CDC panel mulls changes to RSV vaccine recommendation

BioPharma Dive

The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.

Vaccines 112
article thumbnail

What Your Pharmacy Can Do for National Nutrition Month

Digital Pharmacist

Did you know March is National Nutrition Month ? National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise. Springtime, March specifically, is an excellent time of year for you to start conversations with your patients about the various foods they’re eating and how they can enhance their diets to improve

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Planning strategies for transitioning to the Clinical Trials Regulation

pharmaphorum

There is a pressing need for companies to transition their EU clinical trials that are ongoing under the “old” regulatory framework of the Clinical Trials Directive to the Clinical Trials Regulation. The risk for those that don’t meet the 30th January 2025 deadline for transition is that they will lose their legal basis.

119
119
article thumbnail

STAT+: White House to hold a listening session on reforming pharmacy benefit managers

STAT

In a bid to combat prescription drug costs, the White House will hold a listening session on Monday in search of ways to reform pharmacy benefit managers , according to people familiar with the plans. The list of attendees includes representatives from the federal government and industry, who are expected to provide insights into how the largest pharmacy benefit managers determine which medicines are covered by insurers and employers, as well as prices that are paid at pharmacy counters.

360
360
article thumbnail

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

Pharmafile

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

111
111
article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

The Chief Executive of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine, will step down in the Autumn following five years in the role. Dame June will remain in the position until then to support the new Chief Executive’s transition into the role. Leading the MHRA – a five year journey Professor Graham Cooke, interim chair of the MHRA board, remarked that Dame June’s “leadership of the MHRA over the last five years, particularly during the COVID-19 pand

article thumbnail

Rare Disease Day 2024 – The importance of shining a light on rare diseases

pharmaphorum

Rare Disease Day 2024 is an important opportunity to raise awareness about rare diseases and the need for research, diagnosis, and treatment options like orphan drugs. Learn the significance of shining a light on rare diseases.

118
118
article thumbnail

STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

STAT

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

Vaccines 355
article thumbnail

Takeda partner with Biological E. to accelerate access to dengue vaccine

Express Pharma

The partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and Takeda’s long-term partnership with IDT Biologika GmbH Takeda and Biological E. Limited (BE) has announced a strategic partnership to accelerate access to QDENGA▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Vaccines 103
article thumbnail

Obesity drug from Boehringer, Zealand succeeds in MASH trial

BioPharma Dive

Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

114
114
article thumbnail

Pfizer’s new cancer unit sees eight new blockbusters by 2030

pharmaphorum

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

133
133
article thumbnail

STAT+: FTC says pharmacy benefit managers are stonewalling requests for information

STAT

A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because the companies have failed to provide many of the documents that, in some cases, were requested as far back as June 2022. The inquiry was begun by the Federal Trade Commission in response to the role that pharmacy benefit managers play in the cost of prescription medicines.

article thumbnail

Innovations paving the way for drug discovery of rare diseases

Express Pharma

Orphan diseases, also known as rare diseases, are a variety of conditions that affect a small percentage of the population. By definition, rare diseases are those diseases with a prevalence rate of one case in a population of 10,000 people. Rare diseases are of two types: primary and secondary. Primary rare diseases are caused due to genetic or congenital defects.

article thumbnail

Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

Pharmaceutical Technology

AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space

122
122
article thumbnail

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

pharmaphorum

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

115
115
article thumbnail

More than 1 billion people have obesity, including 159 million young people, study estimates

STAT

More than 1 billion people — or one in eight people worldwide — are now estimated to have obesity, a new study finds. Obesity rates grew particularly fast among children and teens, quadrupling from 1990 to 2022, the latest year the analysis looked at, while rates among adults more than doubled. That comes to 159 million children and teens with obesity, and 879 million adults, according to the study, published Thursday in the Lancet and conducted by the NCD Risk Factor Collaboration

356
356
article thumbnail

Nezglyal remains promising therapy despite EMA’s market authorisation refusal: GlobalData

Express Pharma

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the refusal of the marketing authorisation for Nezglyal (leriglitazone). Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is intended for the treatment of cerebral adrenoleukodystrophy (cALD).

100
100
article thumbnail

Semaglutide Compounded Vials 5mg Available Now at Welltopia

Welltopia Pharmacy

Compounded Semaglutide: A Modern Approach to Medication Compounded Semaglutide is a sophisticated version of the widely recognized Semaglutide medication, designed

article thumbnail

Power of digital technology and partnership to accelerate delivery of new medicines to patients

pharmaphorum

Discover how digital technology and strategic partnerships are revolutionising the pharmaceutical industry, enabling faster delivery of life-saving medicines to patients, while advancing humanity's fight against diseases.

116
116
article thumbnail

Cholera vaccine shortage reaches worst point yet, with experts fearing deadly outbreaks

STAT

An unprecedented shortage of cholera vaccine has public health experts fearing that a recent surge of outbreaks across developing countries will only worsen, a situation they argue is as regrettable as it was avoidable. At least 16 countries in Asia, Africa, and the Caribbean are dealing with cholera outbreaks. According to the latest report from the European Centre for Disease Prevention and Control , between Dec. 23 and Jan. 23, nearly 50,500 people contracted cholera and nearly 500 died.

Vaccines 354
article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

article thumbnail

Gritstone to lay off 40% of workforce after costly study delay

BioPharma Dive

The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized vaccine for cancer.

Vaccines 117